A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects

• Status: Completed
• Trial end date: 1969-12-31

Summary

The purpose of this study is to determine whether a simplified lopinavir-ritonavir based therapy will continue to keep the viral load to very low levels after initial treatment with a combination of Kaletra® (lopinavir/ritonavir) plus Combivir® (lamivudine/zidovudine).

• Phase: Phase 2

Details

• Lead Sponsor: Abbott
• Treatments: Efavirenz; Lamivudine; Lamivudine, zidovudine drug combination; Lopinavir; Ritonavir; Zidovudine